viewMGC Pharmaceuticals Ltd

MGC Pharmaceuticals boosted by UK import approval

CannEpil+ will be made available for free on compassionate grounds to ten patients with refractory epilepsy for six months, as part of a trial

MGC Pharmaceuticals Ltd - MGC Pharmaceuticals boosted by UK import approval

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, FRA:H5O, ASX:MXC) has achieved a new landmark for the UK cannabis market as CannEpil+, a Cannabis based treatment for epilepsy, has been approved for import by the UK authorities.

An import permit was issued by the Medicines and Healthcare products Regulatory Agency and the award was enabled by MGC’s UK distribution and clinical access partner Elite Pharmaco.

It is the first time that an epilepsy treatment currently in a clinical trial process, and containing THC, has been approved by the authorities in the UK for import, MGC highlighted.

The company noted that the permit opens a new key strategic market for its leading phytocannabinoid derived medicine.

CannEpil+ will be made available for free on compassionate grounds to ten patients with refractory epilepsy for six months. The treatment will be monitored using a data collection app which will provide real time insights into the efficacy of CannEpil +.

Epilepsy is seen as one of the most common serious neurological conditions, affecting around 600,000 people in the UK (50mln worldwide) - and around 33% of adults, 20-25% of children, suffer from refractory epilepsy (otherwise known as drug resistant epilepsy) which cannot be controlled with traditional anti-seizure medication, MGC noted.

Quick facts: MGC Pharmaceuticals Ltd


Price: 3.1 GBX

Market Cap: £73.93 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


MGC Pharmaceuticals: Continuous global breakthroughs as progress accelerates

Proactive Research Analyst Ed Stacey presents his analysis on MGC Pharmaceuticals (LON:MXC).  The company recently announced that it has received a UK import permit for CannEpil+, which is MGC’s cannabis-derived therapy for refractory epilepsy, to be used initially on a compassionate access...

1 week, 3 days ago

2 min read